No. 24-292

Salix Pharmaceuticals, Ltd., et al. v. Norwich Pharmaceuticals Inc.

Lower Court: Federal Circuit
Docketed: 2024-09-13
Status: Denied
Type: Paid
Experienced Counsel
Tags: appellate-procedure evidence-standard factual-findings harmless-error judicial-review standard-of-review
Key Terms:
Securities Patent Copyright Trademark
Latest Conference: 2024-12-13
Question Presented (AI Summary)

When a district court's findings of fact are unsupported by the evidence the district court relied on, may a court of appeals affirm based on other evidence in the record, particularly when the relevance of that evidence depends on unresolved factual disputes?

Question Presented (from Petition)

QUESTIONS PRESENTED This petition concerns core appellate procedure. In reviewing bench trials, the courts of appeals must “discuss” and “analyze” the district court’s findings, not make factual findings on their own. Icicle Seafoods, Inc. v. Worthington, 475 U.S. 709, 714 (1986). The Federal Circuit disregards this limitation. In the decision below, the panel majority affirmed a judgment based on evidence never credited by the district court. Crediting this evidence required the panel majority to decide a critical factual dispute left unresolved in the district court’s findings. The panel majority’s willingness to find facts in the first instance led to a second error: the district court relied heavily on an impermissible piece of evidence. The decision below holds that this error was harmless because, according to the panel majority’s findings, other evidence “established” the disputed fact. The questions presented are: 1. When a district court’s findings of fact are unsupported by the evidence the district court relied on, may a court of appeals affirm based on other evidence in the record, particularly when the relevance of that evidence depends on unresolved factual disputes. 2. When a district court’s findings of fact rely on impermissible evidence, what standard applies to determine whether the error is harmless.

Docket Entries

2024-12-16
Petition DENIED.
2024-11-26
DISTRIBUTED for Conference of 12/13/2024.
2024-11-26
Reply of petitioners Salix Pharmaceuticals, Ltd., et al. filed. (Distributed)
2024-11-12
Brief of Norwich Pharmaceuticals Inc. in opposition submitted.
2024-11-12
Brief of respondent Norwich Pharmaceuticals Inc. in opposition filed.
2024-10-11
Motion to extend the time to file a response is granted and the time is extended to and including November 14, 2024.
2024-10-09
Motion of Norwich Pharmaceuticals Inc. for an extension of time submitted.
2024-10-09
Motion to extend the time to file a response from October 15, 2024 to November 14, 2024, submitted to The Clerk.
2024-09-11

Attorneys

Norwich Pharmaceuticals Inc.
Thomas Knut HedemannAxinn, Veltrop & Harkrider, LLP, Respondent
Thomas Knut HedemannAxinn, Veltrop & Harkrider, LLP, Respondent
Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Bausch Health Ireland Ltd.
William Robert PetersonMorgan, Lewis & Bockius LLP, Petitioner
William Robert PetersonMorgan, Lewis & Bockius LLP, Petitioner